Increased Response to Arachidonic Acid and U-46619 and Resistance to Inhibitory Prostaglandins in Patients with Chronic Myeloproliferative Disorders

Sergio Cortelazzo; Monica Galli; Donatella Castagna; Piera Viero; Giovanni de Gaetano; Tiziano Barbui

doi:10.1055/s-0038-1642568

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1988; 59(01): 073-076
DOI: 10.1055/s-0038-1642568

Review Article

Schattauer GmbH Stuttgart

Increased Response to Arachidonic Acid and U-46619 and Resistance to Inhibitory Prostaglandins in Patients with Chronic Myeloproliferative Disorders

Sergio Cortelazzo

^*The Reparto di Ematologia, Ospedali Riuniti di Bergamo, Italy

,

Monica Galli

^*The Reparto di Ematologia, Ospedali Riuniti di Bergamo, Italy

,

Donatella Castagna

^*The Reparto di Ematologia, Ospedali Riuniti di Bergamo, Italy

,

Piera Viero

^*The Reparto di Ematologia, Ospedali Riuniti di Bergamo, Italy

,

Giovanni de Gaetano

^**The Reparto di Ematologia, Ospedali Riuniti di Bergamo and Istituto di Ricerche Farmacologiche “Mario Negri“, Centro di Ricerche del Consorzio “Mario Negri Sud”, S. Maria Imbaro, Chieti, Italy

,

Tiziano Barbui

^*The Reparto di Ematologia, Ospedali Riuniti di Bergamo, Italy

› Institutsangaben

Abstract

als PDF herunterladen

Summary

In patients with myeloproliferative disorders (MPD) a group of related diseases of the bone marrow stem cell and recurrent haemorrhagic and/or thrombotic complications, the production of aggregating prostaglandins (PGs) may be normal or slightly reduced, while PGI₂ production is normal. However, MPD platelet sensitivity to antiaggregatory PGs is still unknown.

We studied the potency of PGD₂, PGI₂ and PGEi as inhibitors of platelet aggregation induced by threshold aggregating concentrations of arachidonic acid and U-46619-analogue of the cyclic endoperoxide PGH₂ in 20 patients with MPD in comparison with healthy controls, with the aim of evaluating the sensitivity of MPD platelets to antiaggregatory PGs. In these patients platelet prostanoid metabolism was normal. However, the functional response of platelets to aggregating and antiaggregating prostanoids was shifted towards potentially increased platelet aggregation response. These findings could have a clinical relevance in view of the haemostatic and thrombotic complications so frequent in MPD.

Keywords

Sensitivity - aggregating and antiaggregatory prostaglandins - Thrombotic - haemorrhagic complications - Chronic myeloproliferative disorders

PDF (372 kb)

Referenzen

References
1 Moneada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood vessel wall. N Engl J Med 1979; 300: 1142-1147
2 Di GMinno, Silver MJ, de GGaetano. Prostaglandins as inhibitors of human platelet aggregation. Br J Haematol 1979; 43: 637-647
3 Moneada S, Grylewski RJ, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665
4 Oelz O, Oelz R, Knapp HR, Sweetman BJ, Oates JA. Biosynthesis of prostaglandin D₂ . Prostaglandins 1977; 13: 225-234
5 Whittle B JR, Moneada S, Vane JR. Comparison of the effects of prostacyclin (PGI₂), prostaglandin Ej and D₂ on platelet aggregation in different species. Prostaglandins 1978; 16: 373-388
6 Sinzinger H, Kaliman J, Widhalm K, Pachinger O, Probst P. Value of platelet sensitivity to antiaggregatory prostaglandins (PGI₂, PGE _1?PGD₂) in 50 patients with myocardial infarction at young age.. Prostagland Med 1981; 7: 125-132
7 Fitscha P, Kaliman J, Sinzinger H. Platelet sensitivity to antiaggregatory prostaglandins (PGEj, D₂,1₂) in patients with peripheral vascular disease.. Am J Hematol 1985; 19: 13-19
8 Cooper B, Schafer AI, Puchalsky D, Handin RI. Platelet resistence to prostaglandin D₂ in patients with myeloproliferative disorders. Blood 1978; 52: 618-626
9 Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol 1983; 19: 1593-1599
10 Cortelazzo S, Barbui T, Bassan R, Dini E. Abnormal aggregation and increased size of platelets in myeloproliferative disorders. Thromb Haemostas 1980; 43: 127-130
11 Born G VR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
12 Di GMinno, Bertele V, Bianchi L, Barbieri B, Cerletti C, Dejana E, de GGaetano, Silver MJ. Effects of an epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. Thromb Haemostas 1981; 45: 103-106
13 Bertelè V, Falanga A, Tomasiak M, Chiabrando C, Cerletti C, de GGaetano. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products. Blood 1984; 63: 1460-1466
14 Patrono C, Ciabattoni G, Pinca E, Pugliesi F, Castrucci G, de ASalvo, Satta MA, Peskar A. Low dose aspirin and inhibition of thromboxane B₂ production in healthy subjects. Thromb Res 1980; 17: 317-327
15 Weskler BB, Markus AJ, Jaffe EA. Synthesis of prostaglandin I ₂(prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 1977; 74: 3922-3926
16 Kwaan HC, Colwell JA, Cruz S. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972; 80: 236-246
17 Bensossuan D, Levy-Toledano S, Passa P, Caen J, Canivet J. Platelet hyperaggregation and increased plasma level of von Willebrand factor in diabetics with retinopathy. Diabetologia 1975; 11: 307-312
18 Halushka PV, Lurie D, Colwell JA. Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus. N Engl J Med 1977; 297: 1306-1310
19 Cortelazzo S, Viero P, Morelli C, Barbui T, de GGaetano. Normal vascular prostacyclin generation in patients with chronic myeloproliferative disorders. Thromb Res 1985; 39: 139-141